US$ 23.30
analogues du glp 1 GLP-1 analogs and dual incretin agonists to support weight loss GLP-1-based therapies for type 2
Description
FDA Approves Weight Loss Pill From Eli Lilly

How do we measure outcomesnot just utilization
(2023) reported that semaglutide reduced both baseline and relapse-like alcohol consumption in rats, blunted ethanol-induced hyperlocomotion and NAc dopamine release, and increased expression of dopamine-metabolizing enzymes

Among them, retatrutide has shown significant clinical advantages in phase II clinical trials, reducing the weight of obese patients by up to 24.2% in 48 weeks and lowering the HbA1c of type 2 diabetes patients by 2.2% in 36 weeks (49, 50)
